dc.contributor.author |
Poppitt, Sally |
en |
dc.contributor.author |
McGregor, Robin |
en |
dc.contributor.author |
Wiessing, KR |
en |
dc.contributor.author |
Goyal, VK |
en |
dc.contributor.author |
Chitkara, AJ |
en |
dc.contributor.author |
Gupta, S |
en |
dc.contributor.author |
Palmano, K |
en |
dc.contributor.author |
Kuhn-Sherlock, B |
en |
dc.contributor.author |
McConnell, MA |
en |
dc.date.accessioned |
2014-08-13T22:41:21Z |
en |
dc.date.accessioned |
2015-10-13T23:31:16Z |
en |
dc.date.issued |
2014-08 |
en |
dc.identifier.citation |
Journal of Pediatric Gastroenterology and Nutrition, 2014, 59 (2), pp. 167 - 171 |
en |
dc.identifier.issn |
0277-2116 |
en |
dc.identifier.uri |
http://hdl.handle.net/2292/27203 |
en |
dc.description.abstract |
Rotavirus (RV) is a leading cause of morbidity and mortality in children younger than 5 years of age, presenting commonly with diarrhoeal symptoms. In a prospective 12-week double-blind randomised controlled trial we assessed acceptability and efficacy of a high-ganglioside complex milk lipid (CML) for prevention of RV infection in 450 infants, ages 8 to 24 months, at 3 sites in northern India. Prevalence of diarrhoea and RV was unseasonably low at baseline (all-cause diarrhoea [ACD], n = 16; RV diarrhoea [RVD], n = 2; RV infection, RV positive [RV], n = 20) and throughout the trial, with only 110 total episodes of ACD for 12 weeks (CML, n = 62; control, n = 48) of which 10 were RVD (CML, n = 4; control, n = 6). Mean duration that RVD persisted was lower in the CML group (2.3 ± 0.5 days) than that in the control group (3.8 ± 1.3 days, P = 0.03), but only 3 of 450 end of trial stool samples were identified as RV (<1%; CML, n = 2; control, n = 1). This hampered the assessment of efficacy of CML, despite the large a priori determined sample size. During the trial similar numbers of infants reported adverse events (AEs: CML 41%, control 46%), with the majority of events classified as mild and not related to the intervention. In conclusion, further clinical trials against a higher background of seasonal prevalence are necessary to assess efficacy of this nutritional intervention to prevent RVD. More important, however, high-ganglioside CML was acceptable for long-term consumption in infants ages 8 to 24 months. |
en |
dc.format.medium |
Print |
en |
dc.language |
Eng |
en |
dc.relation.ispartofseries |
Journal of Pediatric Gastroenterology and Nutrition |
en |
dc.relation.replaces |
http://hdl.handle.net/2292/22727 |
en |
dc.relation.replaces |
2292/22727 |
en |
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. Details obtained from http://www.sherpa.ac.uk/romeo/issn/0277-2116/ |
en |
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
en |
dc.title |
Bovine Complex Milk Lipid Containing Gangliosides for Prevention of Rotavirus Infection and Diarrhoea in Northern Indian Infants |
en |
dc.type |
Journal Article |
en |
dc.identifier.doi |
10.1097/mpg.0000000000000398 |
en |
pubs.issue |
2 |
en |
pubs.begin-page |
167 |
en |
pubs.volume |
59 |
en |
dc.identifier.pmid |
25023444 |
en |
pubs.end-page |
171 |
en |
dc.rights.accessrights |
http://purl.org/eprint/accessRights/RestrictedAccess |
en |
pubs.subtype |
Article |
en |
pubs.elements-id |
447378 |
en |
pubs.org-id |
Science |
en |
pubs.org-id |
Biological Sciences |
en |
dc.identifier.eissn |
1536-4801 |
en |
pubs.record-created-at-source-date |
2014-08-14 |
en |
pubs.dimensions-id |
25023444 |
en |